Clinical, Organizational, and Care Impact of the GetReady Digital Platform as a Clinical Decision Support Tool in the Follow-up of Patients With Cerebral Aneurysm (SAFO)
29 avril 2026 mis à jour par: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Smart Aneurysm FOllow-up
This study evaluates the clinical, organizational, and care impact of the GetReady digital platform as a clinical decision support tool for the follow-up of patients with cerebral aneurysm.
The platform integrates clinical, radiological, and patient-reported data, including PROMs and PREMs, and may incorporate home blood pressure monitoring.
The study is an interventional implementation study with retrospective and prospective components.
No additional medical, diagnostic, or therapeutic intervention is introduced, and all clinical decisions remain under routine clinical practice.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
200
Phase
- N'est pas applicable
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Diagnosis of cerebral aneurysm
- Access to one of the following: compatible mobile phone, computer, or tablet with internet access
- Sufficient internet connection for use of the digital platform
- When the patient cannot or does not wish to use the application directly, participation may occur through a designated caregiver or family member, after informed consent
Exclusion Criteria:
- Patients treated with surgical clipping
- Absence of informed consent
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: GetReady Digital Follow-up
Participants with cerebral aneurysm enrolled in a digital follow-up pathway using the GetReady platform in addition to routine clinical care.
The platform is used to collect and integrate clinical, radiological, and patient-reported data, including PROMs and PREMs, and may include home blood pressure monitoring when clinically indicated.
The study does not introduce any additional medical, diagnostic, or therapeutic intervention, and all clinical decisions remain under routine practice.
|
CE-marked digital platform used to support follow-up of patients with cerebral aneurysm through structured collection and visualization of clinical, radiological, and patient-reported data during routine care.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EQ-5D-5L index score at 12 months
Délai: Baseline and 12 months after enrollment
|
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L).
The EQ-5D-5L evaluates mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
The outcome will be reported as the EQ-5D-5L index score.
|
Baseline and 12 months after enrollment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EQ-5D-5L visual analogue scale score at 12 months
Délai: 12 months after enrollment
|
Overall self-rated health status assessed using the EQ-5D-5L Visual Analogue Scale (VAS).
The EQ VAS records the participant's self-rated health on a scale from 0 to 100, with higher scores indicating better perceived health.
|
12 months after enrollment
|
|
PPE-15 total score at hospital discharge or post-procedure assessment
Délai: 30 days after hospital discharge - post diagnostic procedure and post-therapeutic procedure
|
Patient experience assessed using the Picker Patient Experience Questionnaire (PPE-15) in participants who undergo an intervention and hospital admission.
The PPE-15 evaluates patient experience during inpatient care.
The outcome will be reported as the PPE-15 total score.
|
30 days after hospital discharge - post diagnostic procedure and post-therapeutic procedure
|
|
Net Promoter Score reported by patients for the digital platform
Délai: 12 months after enrollment
|
Patient Net Promoter Score (NPS) for the use of the digital platform, calculated as the percentage of promoters (score 9-10) minus the percentage of detractors (score 0-6).
Scores range from -100 to +100, with higher scores indicating greater likelihood to recommend the platform.
|
12 months after enrollment
|
|
Percentage of scheduled PROM and PREM questionnaires completed through the digital platform
Délai: Up to 12 months after enrollment
|
Adherence to digital follow-up measured as the percentage of scheduled patient-reported outcome and patient-reported experience questionnaires completed through the digital platform during follow-up.
|
Up to 12 months after enrollment
|
|
Percentage of participants remaining active on the digital platform at 12 months
Délai: 12 months after enrollment
|
Retention in digital follow-up measured as the percentage of enrolled participants who remain active users of the digital platform at 12 months.
|
12 months after enrollment
|
|
Mean number of in-person follow-up visits per therapeutic procedure within 90 days after treatment
Délai: Within 90 days after therapeutic procedure
|
Utilization of in-person follow-up will be assessed as the ratio of the total number of in-person visits (first visits plus follow-up visits within 90 days after treatment) divided by the number of therapeutic procedures performed during the same period.
|
Within 90 days after therapeutic procedure
|
|
Number of participants readmitted within 30 days after discharge following aneurysm-related therapeutic intervention
Délai: Within 30 days after discharge following therapeutic intervention
|
Readmission will be assessed as the number of participants who, within 30 days after discharge following aneurysm-related therapeutic intervention, have a hospitalization episode associated with diagnosis code of intracranial aneurysm.
|
Within 30 days after discharge following therapeutic intervention
|
|
Number of participants with post-procedural complications within 30 days after discharge following therapeutic intervention
Délai: Within 30 days after discharge following therapeutic intervention
|
Post-procedural complications will be assessed as the number of participants with readmission within 30 days after discharge and/or documentation of clinically relevant complications during follow-up, including subarachnoid hemorrhage when present.
|
Within 30 days after discharge following therapeutic intervention
|
|
Mean length of hospital stay in days per therapeutic procedure
Délai: During the study period, up to January 2029
|
Length of stay will be calculated as the sum of hospital stay duration in hours divided by 24, and then divided by the total number of therapeutic procedures performed during the same period.
The outcome will be reported as mean length of stay in days per therapeutic procedure.
|
During the study period, up to January 2029
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
18 mai 2026
Achèvement primaire (Estimé)
31 décembre 2028
Achèvement de l'étude (Estimé)
31 décembre 2028
Dates d'inscription aux études
Première soumission
22 avril 2026
Première soumission répondant aux critères de contrôle qualité
29 avril 2026
Première publication (Réel)
6 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
6 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
29 avril 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IIBSP-SAF-2025-114
- GA 101172997 (Autre subvention/numéro de financement: HORIZON-IHI)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .